Ophthalmic compositions and methods for treating ophthalmic conditions

a technology of ophthalmic conditions and compositions, applied in the field of ophthalmic compositions, can solve the problems of limited penetration of therapeutic agents through the outer blood-retinal barrier, side effects that are often too substantial for ophthalmic use, and limited compounds into the rp

Inactive Publication Date: 2006-01-12
ALLERGAN INC
View PDF98 Cites 126 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0014] The composition is effective, after being placed into the interior of the eye, to form a delayed release composition, such as a drug delivery element, effective to ...

Problems solved by technology

However, systemic administration of steroids is often associated with side effects that are often too substantial for ophthalmic use.
As such, permeation of compounds into the RPE is quite limited.
Thus, regardless of the administration route, penetration of a therapeutic agent through the outer blood...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0018] The present invention involves compositions, such as ophthalmic compositions, that provide therapy to a patient. In accordance with the disclosure herein, compositions are disclosed that are useful for placement, preferably by injection, into the interior of an eye of a human or animal, and preferably a living human or animal. Such compositions are preferably administered into an eye of a patient in a fluid form, such as a liquid. By administering the compositions as a fluid, the administration may occur without forming an incision in the eye. The liquid composition becomes less fluid when placed in the eye, thereby forming an extended release drug delivery element. For example, the composition becomes a solid, a semi-solid, or a moldable drug-releasing element when placed in the eye. The element is effective in providing prolonged delivery of a therapeutic agent or agents to the eye, for example, to a posterior segment of the eye, or an anterior segment of the eye. The eleme...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Compositionaaaaaaaaaa
Solubility (mass)aaaaaaaaaa
Miscibilityaaaaaaaaaa
Login to view more

Abstract

Compositions, and methods of using such compositions, useful for placement, for example injection, into the interior of human or animal eyes are provided. Such compositions include a therapeutic component, such as one or more corticosteroids, a biocompatible polymeric component, and a solvent component. The composition is in a fluid form before placement in the interior of an eye, and becomes less fluid after the composition is placed in the eye to form an extended or delayed release drug delivery element or system. The drug delivery element is formed by the dissipation of the solvent from the composition when the composition is placed in the interior of an eye. One example of a composition includes triamcinolone acetonide as a therapeutic agent. A method of treating an ophthalmic condition, or otherwise improving or enhancing vision of a patient, comprises placing the fluid composition in the interior of the eye. The method may be practiced by injecting the fluid composition into the interior of the eye.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS [0001] The present application claims the benefit of U.S. Application No. 60 / 587,092, filed Jul. 12, 2004, the content of which in its entirety is hereby incorporated by reference.BACKGROUND [0002] The present invention relates to ophthalmic compositions that are delivered to the interior of an eye of a human or animal. More particularly, the invention relates to ophthalmically acceptable compositions including one or more therapeutic agents. Such compositions are advantageously intraocularly placed into the interior of an eye and form solid or semi-solid drug delivery elements in situ that are effective in providing extended or delayed release of the therapeutic agent or agents into the eye. [0003] Steroids, for example corticosteroids, among other agents, are utilized to treat a wide variety of ophthalmic diseases that affect the posterior segment of an eye. Examples of some diseases treated with corticosteroids include: central retinal vein...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/44
CPCA61K9/0051A61K47/34A61K31/573A61K31/44A61K31/57A61K31/56A61K31/575A61K31/58A61P27/02A61P29/00A61P31/12A61P33/02A61P35/00A61K9/0024A61K9/0048A61K47/38A61K45/06
Inventor WHITCUP, SCOTT M.
Owner ALLERGAN INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap